Evotec SE
Company Profile
Business description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Contact
Essener Bogen 7
Manfred Eigen Campus
Hamburg22419
DEUT: +49 40560810
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
4,766
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,467.00 | 4.40 | 0.05% |
CAC 40 | 7,853.56 | 109.81 | 1.42% |
DAX 40 | 23,734.73 | 235.41 | 1.00% |
Dow JONES (US) | 41,249.38 | 119.07 | -0.29% |
FTSE 100 | 8,585.80 | 31.00 | 0.36% |
HKSE | 23,549.46 | 681.72 | 2.98% |
NASDAQ | 17,928.92 | 0.78 | 0.00% |
Nikkei 225 | 37,644.26 | 140.93 | 0.38% |
NZX 50 Index | 12,676.75 | 71.68 | 0.57% |
S&P 500 | 5,659.91 | 4.03 | -0.07% |
S&P/ASX 200 | 8,233.50 | 2.30 | 0.03% |
SSE Composite Index | 3,369.24 | 27.25 | 0.82% |